Advanced Biomed Inc. (ADVB) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2026, Advanced Biomed reported revenue of $127,637. Net income was $6.7M (a 5231.3% net margin), or $5.33 per diluted share. Operating margin was -4883.8%. Operating activities generated -$1.9M of cash. At fiscal year end, Advanced Biomed held $13.8M in total assets against $1.5M in total liabilities.
Open the full interactive Advanced Biomed financials → Quarterly statements, key ratios, valuation history and price charts.
Advanced Biomed Key Stats
| Share Price | $5.16 |
|---|---|
| Market Cap | $6.5M |
| P/E Ratio | 1.0 |
| 52-Week Range | $3.71 – $18.98 |
| Shares Outstanding | 1.3 million (basic, 2026 Q4) |
Advanced Biomed Income Statement
| FY 2025 | FY 2026 | |
|---|---|---|
| Revenue | $0 | $127,637 |
| Operating Income | — | -$6.2M |
| Pre-Tax Income | -$3.3M | -$6.3M |
| Income Tax | — | -$1,205 |
| Net Income | -$3.3M | $6.7M |
| Diluted EPS | -$3.20 | $5.33 |
Advanced Biomed Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $127,637 |
| Net Income | -$386,901 | $6.9M | -$488,942 | $694,999 |
| Diluted EPS | -$0.40 | $6.20 | -$0.38 | $0.55 |
Advanced Biomed Balance Sheet
| FY 2025 | FY 2026 | |
|---|---|---|
| Current Assets | $6.0M | $13.7M |
| Total Assets | $6.5M | $13.8M |
| Current Liabilities | $2.9M | $1.5M |
| Total Liabilities | $3.0M | $1.5M |
| Shareholders' Equity | $3.5M | $12.3M |
Advanced Biomed Cash Flow Statement
| FY 2025 | FY 2026 | |
|---|---|---|
| Cash From Operations | -$5.8M | -$1.9M |
| Cash From Investing | -$31,650 | -$2.5M |
| Cash From Financing | $5.9M | $2.0M |
| Free Cash Flow | -$5.9M | — |
Figures from Advanced Biomed's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Advanced Biomed financials page for every line item.
Advanced Biomed Company Profile
| Ticker | ADVB |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | Reno, Nevada |
| Incorporated in | Nevada |
| Fiscal Year End | June 30 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001941029 |
Frequently Asked Questions
What was Advanced Biomed's revenue in fiscal 2026?
Advanced Biomed (ADVB) reported revenue of $127,637 for fiscal 2026.
What was Advanced Biomed's net income in fiscal 2026?
Advanced Biomed reported net income of $6.7M for fiscal 2026.
What was Advanced Biomed's earnings per share (EPS) in fiscal 2026?
Advanced Biomed's diluted EPS was $5.33 for fiscal 2026 (adjusted for any later stock splits).
What was Advanced Biomed's revenue last quarter?
In its most recent reported quarter (2026 Q4), Advanced Biomed reported revenue of $127,637.
How many shares of Advanced Biomed are outstanding?
Advanced Biomed reported a weighted average of 1.3 million basic shares outstanding in 2026 Q4.
What is Advanced Biomed's market cap?
Based on its latest closing price, Advanced Biomed (ADVB) has a market capitalization of about $6.5M.
When does Advanced Biomed's fiscal year end?
Advanced Biomed's fiscal year end, as registered with the SEC, is June 30.
Where is Advanced Biomed headquartered?
Advanced Biomed lists its business address in Reno, Nevada in its SEC filings.